Results 21 to 30 of about 34,445,663 (284)

Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?

Advances in Perioperative Care
In recent years, concerns have arisen regarding the perioperative use of glucagon-like peptide-1 receptor agonist medications and a possible association with increased risk of pulmonary aspiration. The evidence in this setting remains limited.
Louisa Frances Lowes
doaj   +2 more sources

Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis [PDF]

, 2020
Purpose: To compare the effectiveness of glucagon-like peptide 1 receptor agonist with that of basal insulin in type 2 diabetes patients. Methods: Type-2 diabetes patients who were insensitive to metformin were treated with glucagon-like peptide 1 ...
Chen, Xiaxia, Lv, Qi, Lin, Kaiping, Lin, Ting, Yang, Xiaoling, Feng, Min   +5 more
core   +1 more source

Glucagon-like peptide-1 receptor agonists in orthopaedics

SICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery. There is growing amount of evidence of their ability to modulate the activity of osteoblasts and osteoclasts, affect inflammatory
Mavrogenis, Andreas, Altsitzioglou, Pavlos, Pililis, Sotirios, Anastasilakis, Athanasios, Tournis, Symeon, Makras, Polyzois, Saranteas, Theodosis, Lustig, Sebastien   +7 more
openaire   +3 more sources

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Case Reports in Gastrointestinal Medicine, 2021
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of ...
Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi   +4 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.

JAMA Netw Open
This cohort study evaluates glucagon-like peptide-1 (GLP-1) receptor agonist switching patterns and 12-month adherence and persistence among adults with overweight or obesity without ...
Xie L, Anazco D, Chancay AH, Mathew MS, Francis JM, Almandoz JP, Messiah SE.   +6 more
europepmc   +2 more sources

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking ...
Osman Corbali, Priyanka Menon, Halil I. Corbali, Ram Jagannathan, Allan I. Levey   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain. [PDF]

PLoS ONE, 2014
Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic β-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM).
Graham M West, Francis S Willard, Kyle W Sloop, Aaron D Showalter, Bruce D Pascal, Patrick R Griffin   +5 more
doaj   +1 more source